Art

J-GLOBAL ID：201702253178631257   Reference number：17A1943306

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

BRAF^V600変異陽性転移性メラノーマ患者でのベムラフェニブ:ランダム化BRIM-3試験の最終全生存率結果

Author (19)： CHAPMAN P. B. (Memorial Sloan Kettering Cancer Center, New York, USA) ,  ROBERT C. (Paris Sud Univ., Paris, FRA) ,  LARKIN J. (Royal Marsden NHS Foundation Trust, London, GBR) ,  HAANEN J. B. (Netherlands Cancer Inst., Amsterdam, NLD) ,  RIBAS A. (Univ. California, Los Angeles, USA) ,  HOGG D. (Univ. Health Network, Toronto, CAN) ,  HAMID O. (Melanoma Therapeutics, Los Angeles, USA) ,  ASCIERTO P. A. (Istituto Nazionale Tumori Fondazione G. Pascale, Naples) ,  TESTORI A. (Istituto Europeo di Oncologia, Milan, ITA) ,  LORIGAN P. C. (Univ. Manchester, Manchester, GBR) ,  DUMMER R. (Univ. Zurich, Zurich, CHE) ,  SOSMAN J. A. (Northwestern Univ., Chicago) ,  FLAHERTY K. T. (Massachusetts General Hospital, Boston) ,  CHANG I. (Genentech Inc., South San Francisco, USA) ,  COLEMAN S. (Genentech Inc., South San Francisco, USA) ,  CARO I. (Genentech Inc., South San Francisco, USA) ,  HAUSCHILD A. (Univ. Hospital Schleswig-Holstein, Kiel, DEU) ,  MCARTHUR G. A. (Peter MacCallum Cancer Centre, East Melbourne) ,  MCARTHUR G. A. (Univ. Melbourne, Parkville, AUS)
Material： Annals of Oncology  (Ann Oncol)
Volume： 28  Issue： 10  Page： 2581-2587  Publication year： Oct. 2017 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： BRAF gene ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1943306&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Skin tumors(=neoplasms)  (GF04000X)

Substance index (2)： Dacarbazine ,  Vemurafenib

Reference (18)：

• Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
• Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
• Hauschild A, Grob J-J, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
• Masuda S, Izpisua Belmonte JC. Trametinib for patients with advanced melanoma. Lancet Oncol 2012; 13: e409-e410.
• Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.

Terms in the title (7)： 変異 ,  転移性メラノーマ ,  患者 ,  ベムラフェニブ ,  ランダム化 ,  試験 ,  全生存率